Developer docs
API playgroundTry for free, no card

Search company profiles

Aligning Science Across Parkinson's

Full company profile

uuid005rhm4

Namestring
Aligning Science Across Parkinson's
Legal namestring
Aligning Science Across Parkinson's
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Aligning Science Across Parkinson's (ASAP) is a global nonprofit research initiative founded in 2017 and headquartered in Chevy Chase, Maryland, with the Coalition for Aligning Science (CAS) serving as managing entity and The Michael J. Fox Foundation for Parkinson's Research (MJFF) as implementation partner. Its mission is to accelerate Parkinson's disease discovery by funding multidisciplinary, multi-institutional research and enforcing an open-science operating model in which funded outputs (data, code, protocols, and lab materials) must be shared in community-recognized repositories under CC BY 4.0 or CC0 licensing. The initiative reaches its 'customers' — academic and clinical investigators worldwide — through competitive grant programs, a scientific advisory board chaired by Nobel laureate Randy Schekman, a network spanning 187 institutions across 24 countries, and standardized event/training programming.

The organization operates three flagship programs. The Collaborative Research Network (CRN), launched in 2020, is a first-of-its-kind community of 67 multidisciplinary teams comprising nearly 400 investigators that address high-priority questions in Parkinson's biology. The Global Parkinson's Genetics Program (GP2) is an international effort to genotype over 250,000 volunteers with a focus on ancestral diversity, with data released iteratively through the AMP® PDRD platform on Terra and Verily Workbench (12th release in July 2026 added 21,156 genotyped and 25,046 WGS participants). The Parkinson's Precision Medicine Initiative (PPMI), renamed in 2025 after 15 years and over $800 million in cumulative investment, is a longitudinal observational study with 4,200+ in-clinic participants across 50 sites in 12 countries and 47,000+ online participants, whose data has been downloaded more than 50 million times. Underpinning these programs are shared infrastructure products: the CRN Cloud (a controlled-access multi-omics analysis platform co-developed with Verily, DNAstack, and DataTecnica and launched June 2024), the ASAP Output Catalog, and standardized lab materials including CRISPR cell lines and viral vectors.

ASAP does not sell products or services and has no commercial pricing model. Its revenue is philanthropic: the Sergey Brin Family Foundation and Catalyst4 (via CNS Quest) provide large-scale philanthropic capital, with grants administered in partnership with MJFF. Total deployed commitments exceed $550 million in the CRN and $800 million in PPMI, with a $261 million CRN funding round announced in April 2026 adding 32 international teams. Operating headcount is 11-50 employees. Go-to-market is community-led: investigators apply through competitive calls published on parkinsonsroadmap.org and MJFF's grant portal, and grantees are bound by ASAP's five-component Open Science Policy, monitored via a custom Hub system.

Short descriptiontext

Aligning Science Across Parkinson's (ASAP) is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through the Collaborative Research Network, Global Parkinson's Genetics Program, and Parkinson's Precision Medicine Initiative, supporting 67 research teams across 187 institutions in 24 countries under an open-science mandate.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Parkinson's disease research, collaborative research networks, open science data sharing, biomedical grant funding, multi-omics research platforms
Industry4 codes
1Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
CodeHLAJAOAMPrimaryYes
2Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
CodeBPAGACAAPrimaryNo
3Electronic Data Capture (EDC) Platforms
CodeHLACAOAAPrimaryNo
4Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
CodeHLACAOAMPrimaryNo
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Membership Organizations8600
  • Services-Commercial Physical & Biological Research8731
Product category
Parkinson's Disease Research Funding
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Grant funding and philanthropic investment
TypeData Monetisation
Description

ASAP is funded through large-scale philanthropic investment and grants. Primary funders include the Sergey Brin Family Foundation (via CNS Quest), with grants administered in partnership with The Michael J. Fox Foundation. ASAP awards competitive grants to research teams globally through its Collaborative Research Network (CRN), Global Parkinson's Genetics Program (GP2), and Parkinson's Precision Medicine Initiative (PPMI). The initiative does not generate commercial revenue from products or services.

parkinsonsroadmap.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Others, Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ASAP is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through competitive multi-year grants to multidisciplinary, multi-institutional research teams under three flagship programs (CRN, GP2, PPMI). It also generates and openly distributes research-enabling resources, including harmonized multi-omics datasets (via the CRN Cloud platform), biosample repositories, CRISPR cell lines and viral vectors, protocols, code, and software, and provides access to training and professional development. The initiative operates under a mandatory open science policy requiring grantees to share data, code, protocols, and lab materials openly under CC BY 4.0 or CC0 licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 550 million investment in the Collaborative Research Network (CRN), funding 67 teams across 187 institutions in 24 countries
+5 more records
Product overview1 text field

Aligning Science Across Parkinson's (ASAP) is a global research initiative (not a product company) that funds and coordinates Parkinson's disease research through three flagship programs: the Collaborative Research Network (CRN), the Global Parkinson's Genetics Program (GP2), and the Parkinson's Precision Medicine Initiative (PPMI). These programs are supported by infrastructure products including the CRN Cloud (a multi-omics data-sharing platform built on Verily Workbench), the ASAP Output Catalog (listing grantee research outputs), the MoMa award program (for meta-analysis of CRN Cloud data), and the Discover ASAP video series (spotlighting network findings). ASAP also runs funding programs including the GBA1 Parkinson's Disease Research Catalyst Program and the Immune Profiling Insights Program, alongside the Open Science Champions recognition program and LRRK2 Central webinar series.

Product and service9 records
1Collaborative Research Network (CRN)
Categorycore research program
Description

A first-of-its-kind global community of 67 multidisciplinary and multi-institutional research teams working together to spark new discoveries in Parkinson's disease research, utilizing open science principles to accelerate discoveries, foster collaboration, generate research-enabling resources, and share data assets within a global network spanning nearly 400 investigators across 187 institutions in 24 countries.

2Global Parkinson's Genetics Program (GP2)
Categorycore research program
Description

Ambitious resource program to understand the genetic architecture of Parkinson's disease through genotyping over 250,000 volunteers worldwide, with a commitment to ancestral diversity and open data sharing via the AMP® PDRD platform. Hundreds of member organizations contribute diverse cohorts to support Parkinson's genetics research at global scale.

3Parkinson's Precision Medicine Initiative (PPMI)
Categorycore research program
Description

Landmark observational study designed to define Parkinson's by biology, identify it earlier, and build more targeted approaches to treatment. PPMI operates a global biorepository and clinical dataset available to academia and industry for biomarker and therapeutic research, with 4,200+ in-clinic participants across 50 sites in 12 countries and more than 47,000 online participants.

4CRN Cloud
Categorydata platform
Description

Controlled-access data-sharing and analysis platform housing harmonized multi-omics datasets from 600+ human postmortem brain donors and other models, enabling meta-analysis through Verily Viewpoint Workbench and supporting collaboration across the global Parkinson's research community. Data includes transcriptomics, proteomics, metabolomics, lipidomics, iPSC, PBMC, CSF, immunology, and biomarker datasets.

5ASAP Output Catalog
Categoryresource catalog
Description

Publicly accessible catalog listing ASAP-funded research outputs including articles, code, datasets, lab materials, and protocols developed by grantees, enabling the global scientific community to discover and reuse ASAP-network research outputs.

6Parkinson's Precision Medicine Initiative Write Now Initiative
Categoryfunding program
Description

Funding program encouraging PPMI investigators (fellows or assistant professors within their first five years) to engage with PPMI data and generate publications furthering the understanding of Parkinson's disease pathophysiology and treatment.

7CRN Multi-Omics Meta-Analysis (MoMa) Award Program
Categoryfunding program
Description

Funding opportunity supporting CRN researchers in conducting meta-analysis of omics data housed within the publicly accessible CRN Cloud, guided by ASAP's open science approach.

8GBA1 Parkinson's Disease Research Catalyst Program
Categoryfunding program
Description

Funding program developed by The Michael J. Fox Foundation in partnership with ASAP to build a deeper, globally integrated understanding of GBA1-associated Parkinson's disease through cross-cohort analyses and systematic model characterization.

9Immune Profiling Insights Program
Categoryfunding program
Description

Program developed by MJFF in partnership with ASAP supporting research that deepens understanding of how specific components of the immune system contribute to Parkinson's disease risk, onset, and progression.

Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1The Michael J. Fox Foundation for Parkinson's Research (MJFF)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

MJFF serves as ASAP's implementation partner, with a track record for operational excellence and commitment to accelerating the next generation of Parkinson's disease treatments. MJFF administers grants and provides operational support for the initiative. In 2026, MJFF announced PPMI's renaming to the Parkinson's Precision Medicine Initiative after 15 years and over $800 million invested.

parkinsonsroadmap.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Coalition for Aligning Science (CAS) serves as the managing entity for the ASAP initiative, setting the strategy and vision. CAS has a track record for designing and implementing large-scale biomedical research programs to accelerate discoveries.

3AMP® PDRD (Accelerating Medicines Partnership in Parkinson's Disease and Related Disorders)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

AMP® PDRD is a public-private partnership between the NIH, multiple biopharmaceutical and life science companies, and nonprofit organizations managed through the Foundation for the NIH (FNIH). ASAP is a partner, with both GP2 and PPMI cohorts sharing data on this platform. The partnership aims to harmonize Parkinson's datasets and identify biomarkers.

parkinsonsroadmap.org
4Plan S / cOAlition S
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ASAP is a member of Plan S, an international initiative requiring that scientific publications resulting from publicly funded research be published in compliant Open Access journals or platforms. Supported by cOAlition S, an international consortium of research funding and performing organizations.

parkinsonsroadmap.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ASAP is a member of the Open Research Funders Group, a partnership of funding organizations committed to the open sharing of research outputs. ORFG engages philanthropies in a community of practice to develop and advance strategies that accelerate access to funded research.

6Incentivizing Collaborative and Open Research (ICOR)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ASAP is an active member of ICOR, an organization working to incentivize collaborative and open research practices across the scientific community.

parkinsonsroadmap.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ASAP is an organizational member of the Research Software Alliance, dedicated to advancing the research software ecosystem by collaborating with decision-makers and key influencers.

Strategic tierCoreTypeTechnology or Integration
Description

Verily collaborated with ASAP, MJFF, DNAstack, and DataTecnica to develop the CRN Cloud platform. Verily's Workbench is used for data analysis within the CRN Cloud ecosystem, enabling researchers to perform and share analyses on the harmonized Parkinson's datasets.

Strategic tierCoreTypeTechnology or Integration
Description

DNAstack collaborated with ASAP, MJFF, Verily, and DataTecnica to develop the CRN Cloud platform, contributing to data infrastructure for the Parkinson's research community.

Strategic tierCoreTypeTechnology or Integration
Description

DataTecnica collaborated with ASAP, MJFF, Verily, and DNAstack to develop the CRN Cloud platform, supporting data infrastructure for the Parkinson's research community.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaborator of ASAP. The Allen Institute conducts neuroscience research and contributes to the collaborative research ecosystem supporting Parkinson's disease research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner of ASAP, contributing to the broader Parkinson's research ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner of ASAP, contributing to the global Parkinson's research ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner of ASAP, contributing to the global Parkinson's research ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Disease-specific research foundation funding large-scale, multi-institutional, open-science programs for Huntington's disease. Operates a virtual R&D model very similar to ASAP's CRN — coordinated network of academic and industry collaborators working toward a single neurodegenerative disease.

TypeBroad incumbent
Description

Philanthropically funded neuroscience research organization producing large-scale, open-access datasets and tools (e.g., Allen Brain Atlas). Comparable to ASAP in producing openly shared neuroscience data assets and in long-term philanthropic funding structure.

TypeBroad incumbent
Description

Largest private biomedical research organization in the US, supporting hundreds of investigators across basic neuroscience and disease biology. Overlaps with ASAP in biomedical research funding scope but operates a fundamentally different investigator-empowerment model rather than disease-focused coordination.

TypeDirect peer
Description

Major disease-specific nonprofit that funds ALS research globally, including multi-institutional collaborations and translational programs. Comparable to ASAP in mission, donor-funded research model, and pipeline-acceleration focus on a fatal neurodegenerative disease.

TypeBroad incumbent
Description

Disease-specific (cancer immunology) nonprofit that funds investigator-initiated research and multi-institutional collaborations. Operates a similar grant-making and consortium model to ASAP, applied to a different disease domain.

6The Michael J. Fox Foundation for Parkinson's Research
TypeDirect peer
Description

ASAP's core implementation partner and the largest private Parkinson's research funder globally. Both organizations operate grant-making models focused on accelerating Parkinson's discovery, share governance over PPMI, and co-administer CRN funding — making them the closest functional mirror to ASAP.

TypeDirect peer
Description

Disease-specific (Alzheimer's) research funding foundation that supports translational and preclinical programs globally. Comparable to ASAP in its focus on a single neurodegenerative disease, grant-making model, and emphasis on biomarker and therapeutic acceleration.

TypeDirect peer
Description

Nonprofit funder supporting targeted, high-risk Alzheimer's research with a model emphasizing principal-investigator grants and collaborative networks — analogous to ASAP's CRN approach but applied to a different neurodegenerative disease.

TypeDirect peer
Description

Parent managing entity of ASAP that designs and implements large-scale biomedical research programs. Shares governance, leadership, and strategic direction with ASAP, and operates analogous alignment-oriented programs across other disease areas within CNS Quest.

TypeDirect peer
Description

Large-scale, philanthropically funded programs that deploy multi-hundred-million-dollar catalytic capital to accelerate breakthroughs in human health. Shares ASAP's model of ambitious, multi-institutional, time-bound research funding outside traditional grant cycles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aligning Science Across Parkinson's

Parkinson's Disease Research Fundingparkinsonsroadmap.org

Aligning Science Across Parkinson's (ASAP) is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through the Collaborative Research Network, Global Parkinson's Genetics Program, and Parkinson's Precision Medicine Initiative, supporting 67 research teams across 187 institutions in 24 countries under an open-science mandate.

What Aligning Science Across Parkinson's does

Aligning Science Across Parkinson's (ASAP) is a global nonprofit research initiative founded in 2017 and headquartered in Chevy Chase, Maryland, with the Coalition for Aligning Science (CAS) serving as managing entity and The Michael J. Fox Foundation for Parkinson's Research (MJFF) as implementation partner. Its mission is to accelerate Parkinson's disease discovery by funding multidisciplinary, multi-institutional research and enforcing an open-science operating model in which funded outputs (data, code, protocols, and lab materials) must be shared in community-recognized repositories under CC BY 4.0 or CC0 licensing. The initiative reaches its 'customers' — academic and clinical investigators worldwide — through competitive grant programs, a scientific advisory board chaired by Nobel laureate Randy Schekman, a network spanning 187 institutions across 24 countries, and standardized event/training programming.

The organization operates three flagship programs. The Collaborative Research Network (CRN), launched in 2020, is a first-of-its-kind community of 67 multidisciplinary teams comprising nearly 400 investigators that address high-priority questions in Parkinson's biology. The Global Parkinson's Genetics Program (GP2) is an international effort to genotype over 250,000 volunteers with a focus on ancestral diversity, with data released iteratively through the AMP® PDRD platform on Terra and Verily Workbench (12th release in July 2026 added 21,156 genotyped and 25,046 WGS participants). The Parkinson's Precision Medicine Initiative (PPMI), renamed in 2025 after 15 years and over $800 million in cumulative investment, is a longitudinal observational study with 4,200+ in-clinic participants across 50 sites in 12 countries and 47,000+ online participants, whose data has been downloaded more than 50 million times. Underpinning these programs are shared infrastructure products: the CRN Cloud (a controlled-access multi-omics analysis platform co-developed with Verily, DNAstack, and DataTecnica and launched June 2024), the ASAP Output Catalog, and standardized lab materials including CRISPR cell lines and viral vectors.

ASAP does not sell products or services and has no commercial pricing model. Its revenue is philanthropic: the Sergey Brin Family Foundation and Catalyst4 (via CNS Quest) provide large-scale philanthropic capital, with grants administered in partnership with MJFF. Total deployed commitments exceed $550 million in the CRN and $800 million in PPMI, with a $261 million CRN funding round announced in April 2026 adding 32 international teams. Operating headcount is 11-50 employees. Go-to-market is community-led: investigators apply through competitive calls published on parkinsonsroadmap.org and MJFF's grant portal, and grantees are bound by ASAP's five-component Open Science Policy, monitored via a custom Hub system.

Aligning Science Across Parkinson's firmographics

Firmographics
Name
Aligning Science Across Parkinson's
Legal name
Aligning Science Across Parkinson's
Website
https://parkinsonsroadmap.org
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Aligning Science Across Parkinson's (ASAP) is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through the Collaborative Research Network, Global Parkinson's Genetics Program, and Parkinson's Precision Medicine Initiative, supporting 67 research teams across 187 institutions in 24 countries under an open-science mandate.
Ownership category
akta.pro rank

Aligning Science Across Parkinson's industry classification

Industry
Product category
Parkinson's Disease Research Funding
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)
akta.pro secondary industries
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Electronic Data Capture (EDC) Platforms (HLACAOAA), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

Keywords

  • Parkinson's disease research
  • Collaborative research networks
  • Open science data sharing
  • Biomedical grant funding
  • Multi-omics research platforms

Where Aligning Science Across Parkinson's is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aligning Science Across Parkinson's business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Others, Personnel, Technology or R&D, Operations

Revenue model

  1. Grant funding and philanthropic investment: ASAP is funded through large-scale philanthropic investment and grants. Primary funders include the Sergey Brin Family Foundation (via CNS Quest), with grants administered in partnership with The Michael J. Fox Foundation. ASAP awards competitive grants to research teams globally through its Collaborative Research Network (CRN), Global Parkinson's Genetics Program (GP2), and Parkinson's Precision Medicine Initiative (PPMI). The initiative does not generate commercial revenue from products or services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Aligning Science Across Parkinson's product offering

Product offering

Core offering

ASAP is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through competitive multi-year grants to multidisciplinary, multi-institutional research teams under three flagship programs (CRN, GP2, PPMI). It also generates and openly distributes research-enabling resources, including harmonized multi-omics datasets (via the CRN Cloud platform), biosample repositories, CRISPR cell lines and viral vectors, protocols, code, and software, and provides access to training and professional development. The initiative operates under a mandatory open science policy requiring grantees to share data, code, protocols, and lab materials openly under CC BY 4.0 or CC0 licensing.

Product overview

Aligning Science Across Parkinson's (ASAP) is a global research initiative (not a product company) that funds and coordinates Parkinson's disease research through three flagship programs: the Collaborative Research Network (CRN), the Global Parkinson's Genetics Program (GP2), and the Parkinson's Precision Medicine Initiative (PPMI). These programs are supported by infrastructure products including the CRN Cloud (a multi-omics data-sharing platform built on Verily Workbench), the ASAP Output Catalog (listing grantee research outputs), the MoMa award program (for meta-analysis of CRN Cloud data), and the Discover ASAP video series (spotlighting network findings). ASAP also runs funding programs including the GBA1 Parkinson's Disease Research Catalyst Program and the Immune Profiling Insights Program, alongside the Open Science Champions recognition program and LRRK2 Central webinar series.

Differentiator

Problem solved

Functional benefit

Products and services

  • Collaborative Research Network (CRN) A first-of-its-kind global community of 67 multidisciplinary and multi-institutional research teams working together to spark new discoveries in Parkinson's disease research, utilizing open science principles to accelerate discoveries, foster collaboration, generate research-enabling resources, and share data assets within a global network spanning nearly 400 investigators across 187 institutions in 24 countries.
  • Global Parkinson's Genetics Program (GP2) Ambitious resource program to understand the genetic architecture of Parkinson's disease through genotyping over 250,000 volunteers worldwide, with a commitment to ancestral diversity and open data sharing via the AMP® PDRD platform. Hundreds of member organizations contribute diverse cohorts to support Parkinson's genetics research at global scale.
  • Parkinson's Precision Medicine Initiative (PPMI) Landmark observational study designed to define Parkinson's by biology, identify it earlier, and build more targeted approaches to treatment. PPMI operates a global biorepository and clinical dataset available to academia and industry for biomarker and therapeutic research, with 4,200+ in-clinic participants across 50 sites in 12 countries and more than 47,000 online participants.
  • CRN Cloud Controlled-access data-sharing and analysis platform housing harmonized multi-omics datasets from 600+ human postmortem brain donors and other models, enabling meta-analysis through Verily Viewpoint Workbench and supporting collaboration across the global Parkinson's research community. Data includes transcriptomics, proteomics, metabolomics, lipidomics, iPSC, PBMC, CSF, immunology, and biomarker datasets.
  • ASAP Output Catalog Publicly accessible catalog listing ASAP-funded research outputs including articles, code, datasets, lab materials, and protocols developed by grantees, enabling the global scientific community to discover and reuse ASAP-network research outputs.
  • Parkinson's Precision Medicine Initiative Write Now Initiative Funding program encouraging PPMI investigators (fellows or assistant professors within their first five years) to engage with PPMI data and generate publications furthering the understanding of Parkinson's disease pathophysiology and treatment.
  • CRN Multi-Omics Meta-Analysis (MoMa) Award Program Funding opportunity supporting CRN researchers in conducting meta-analysis of omics data housed within the publicly accessible CRN Cloud, guided by ASAP's open science approach.
  • GBA1 Parkinson's Disease Research Catalyst Program Funding program developed by The Michael J. Fox Foundation in partnership with ASAP to build a deeper, globally integrated understanding of GBA1-associated Parkinson's disease through cross-cohort analyses and systematic model characterization.
  • Immune Profiling Insights Program Program developed by MJFF in partnership with ASAP supporting research that deepens understanding of how specific components of the immune system contribute to Parkinson's disease risk, onset, and progression.

Quantifiable outcome

  • Over 550 million investment in the Collaborative Research Network (CRN), funding 67 teams across 187 institutions in 24 countries
  • +5 more outcomes

Companies that use Aligning Science Across Parkinson's

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Aligning Science Across Parkinson's technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aligning Science Across Parkinson's partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • The Michael J. Fox Foundation for Parkinson's Research (MJFF)coreStrategic or Co-development Partner · 1 January 2020MJFF serves as ASAP's implementation partner, with a track record for operational excellence and commitment to accelerating the next generation of Parkinson's disease treatments. MJFF administers grants and provides operational support for the initiative. In 2026, MJFF announced PPMI's renaming to the Parkinson's Precision Medicine Initiative after 15 years and over $800 million invested.
  • Coalition for Aligning Science (CAS)coreStrategic or Co-development PartnerCoalition for Aligning Science (CAS) serves as the managing entity for the ASAP initiative, setting the strategy and vision. CAS has a track record for designing and implementing large-scale biomedical research programs to accelerate discoveries.
  • AMP® PDRD (Accelerating Medicines Partnership in Parkinson's Disease and Related Disorders)coreStrategic or Co-development PartnerAMP® PDRD is a public-private partnership between the NIH, multiple biopharmaceutical and life science companies, and nonprofit organizations managed through the Foundation for the NIH (FNIH). ASAP is a partner, with both GP2 and PPMI cohorts sharing data on this platform. The partnership aims to harmonize Parkinson's datasets and identify biomarkers.
  • Plan S / cOAlition ScoreStrategic or Co-development PartnerASAP is a member of Plan S, an international initiative requiring that scientific publications resulting from publicly funded research be published in compliant Open Access journals or platforms. Supported by cOAlition S, an international consortium of research funding and performing organizations.
  • Open Research Funders Group (ORFG)coreStrategic or Co-development PartnerASAP is a member of the Open Research Funders Group, a partnership of funding organizations committed to the open sharing of research outputs. ORFG engages philanthropies in a community of practice to develop and advance strategies that accelerate access to funded research.
  • Incentivizing Collaborative and Open Research (ICOR)coreStrategic or Co-development PartnerASAP is an active member of ICOR, an organization working to incentivize collaborative and open research practices across the scientific community.
  • Research Software Alliance (ReSA)coreStrategic or Co-development PartnerASAP is an organizational member of the Research Software Alliance, dedicated to advancing the research software ecosystem by collaborating with decision-makers and key influencers.
  • Verily (Alphabet)coreTechnology or IntegrationVerily collaborated with ASAP, MJFF, DNAstack, and DataTecnica to develop the CRN Cloud platform. Verily's Workbench is used for data analysis within the CRN Cloud ecosystem, enabling researchers to perform and share analyses on the harmonized Parkinson's datasets.
  • DNAstackcoreTechnology or IntegrationDNAstack collaborated with ASAP, MJFF, Verily, and DataTecnica to develop the CRN Cloud platform, contributing to data infrastructure for the Parkinson's research community.
  • DataTecnicacoreTechnology or IntegrationDataTecnica collaborated with ASAP, MJFF, Verily, and DNAstack to develop the CRN Cloud platform, supporting data infrastructure for the Parkinson's research community.
  • Allen InstituteminorStrategic or Co-development PartnerListed as a collaborator of ASAP. The Allen Institute conducts neuroscience research and contributes to the collaborative research ecosystem supporting Parkinson's disease research.
  • Parkinson's FoundationminorStrategic or Co-development PartnerListed as a partner of ASAP, contributing to the broader Parkinson's research ecosystem.
  • Parkinson's UKminorStrategic or Co-development PartnerListed as a partner of ASAP, contributing to the global Parkinson's research ecosystem.
  • Cure Parkinson'sminorStrategic or Co-development PartnerListed as a partner of ASAP, contributing to the global Parkinson's research ecosystem.

Scale indicators18 records

Recent moves6 records

Expansion highlights6 records

Aligning Science Across Parkinson's competitors and assessment

Company assessment

Direct peers

  • CHDI Foundation: Disease-specific research foundation funding large-scale, multi-institutional, open-science programs for Huntington's disease. Operates a virtual R&D model very similar to ASAP's CRN — coordinated network of academic and industry collaborators working toward a single neurodegenerative disease.
  • ALS Association: Major disease-specific nonprofit that funds ALS research globally, including multi-institutional collaborations and translational programs. Comparable to ASAP in mission, donor-funded research model, and pipeline-acceleration focus on a fatal neurodegenerative disease.
  • The Michael J. Fox Foundation for Parkinson's Research: ASAP's core implementation partner and the largest private Parkinson's research funder globally. Both organizations operate grant-making models focused on accelerating Parkinson's discovery, share governance over PPMI, and co-administer CRN funding — making them the closest functional mirror to ASAP.
  • Alzheimer's Drug Discovery Foundation: Disease-specific (Alzheimer's) research funding foundation that supports translational and preclinical programs globally. Comparable to ASAP in its focus on a single neurodegenerative disease, grant-making model, and emphasis on biomarker and therapeutic acceleration.
  • Cure Alzheimer's Fund: Nonprofit funder supporting targeted, high-risk Alzheimer's research with a model emphasizing principal-investigator grants and collaborative networks — analogous to ASAP's CRN approach but applied to a different neurodegenerative disease.
  • Coalition for Aligning Science: Parent managing entity of ASAP that designs and implements large-scale biomedical research programs. Shares governance, leadership, and strategic direction with ASAP, and operates analogous alignment-oriented programs across other disease areas within CNS Quest.
  • Wellcome Leap: Large-scale, philanthropically funded programs that deploy multi-hundred-million-dollar catalytic capital to accelerate breakthroughs in human health. Shares ASAP's model of ambitious, multi-institutional, time-bound research funding outside traditional grant cycles.

Broad incumbents

  • Allen Institute: Philanthropically funded neuroscience research organization producing large-scale, open-access datasets and tools (e.g., Allen Brain Atlas). Comparable to ASAP in producing openly shared neuroscience data assets and in long-term philanthropic funding structure.
  • Howard Hughes Medical Institute: Largest private biomedical research organization in the US, supporting hundreds of investigators across basic neuroscience and disease biology. Overlaps with ASAP in biomedical research funding scope but operates a fundamentally different investigator-empowerment model rather than disease-focused coordination.
  • Cancer Research Institute: Disease-specific (cancer immunology) nonprofit that funds investigator-initiated research and multi-institutional collaborations. Operates a similar grant-making and consortium model to ASAP, applied to a different disease domain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aligning Science Across Parkinson's social profiles

Digital presence

Aligning Science Across Parkinson's financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aligning Science Across Parkinson's leadership team

Management profile

Number of profiles

Profiles4 records

Aligning Science Across Parkinson's funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aligning Science Across Parkinson's M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aligning Science Across Parkinson's

What does Aligning Science Across Parkinson's do?

ASAP is a global nonprofit research initiative that funds and coordinates Parkinson's disease research through competitive multi-year grants to multidisciplinary, multi-institutional research teams under three flagship programs (CRN, GP2, PPMI). It also generates and openly distributes research-enabling resources, including harmonized multi-omics datasets (via the CRN Cloud platform), biosample repositories, CRISPR cell lines and viral vectors, protocols, code, and software, and provides access to training and professional development. The initiative operates under a mandatory open science policy requiring grantees to share data, code, protocols, and lab materials openly under CC BY 4.0 or CC0 licensing.

Is Aligning Science Across Parkinson's a public or private company?

Aligning Science Across Parkinson's is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Aligning Science Across Parkinson's founded?

Aligning Science Across Parkinson's was founded in 2017. It employs 11 to 50 people.

Where is Aligning Science Across Parkinson's based?

Aligning Science Across Parkinson's is headquartered in Washington, United States, in the North America region.

How does Aligning Science Across Parkinson's make money?

One revenue line is on record: grant funding and philanthropic investment.

Who are Aligning Science Across Parkinson's's main competitors?

Direct peers on record are CHDI Foundation, ALS Association, The Michael J. Fox Foundation for Parkinson's Research, Alzheimer's Drug Discovery Foundation, Cure Alzheimer's Fund, Coalition for Aligning Science and Wellcome Leap. Broad incumbents are Allen Institute, Howard Hughes Medical Institute and Cancer Research Institute.

Does Aligning Science Across Parkinson's have an API?

No public API is recorded for Aligning Science Across Parkinson's.

What industry is Aligning Science Across Parkinson's in?

Aligning Science Across Parkinson's's product category is Parkinson's Disease Research Funding. Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs), with a secondary code of BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 5417 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsIU Brain Powerhouse Tackles Inflammation in Parkinson's FightIU School of Medicine researchers are investigating immune cell exhaustion as a cause of Parkinson's disease, shifting focus from the brain to systemic factors. The work is supported by a $9 million grant from Aligning Science Across Parkinson's and the Michael J. Fox Foundation. The team aims to identify early warning signs and develop therapies that reinvigorate the immune system.ZawyaInternational team led by WCM-Q professor awarded $9mln global Parkinson’s research grantWeill Cornell Medicine-Qatar professor Hilal Lashuel received a $9 million three-year grant from ASAP and MJFF to lead an international team studying Parkinson's disease. The team, including Stanford collaborators and Arvinas, will target toxic protein aggregates to inform future therapies. The project builds on prior research and aims to address protein clearance failures.ParkinsonsnewstodayResearch team wins grant to study Parkinson’s genetics in miceA University of Minnesota Medical School research team has received a $6 million grant from Aligning Science Across Parkinson's and The Michael J. Fox Foundation to develop mouse models for studying genetic variants linked to Parkinson's disease, joining the Collaborative Research Network. The funding is part of a broader $261 million investment that added 32 teams to the network, which aims to advance understanding of disease variation among individuals with Parkinson's. The team's work will focus on replacing mouse genes with corresponding human DNA segments to better understand how genetic factors contribute to Parkinson's and to enable preclinical testing of potential treatments.AijournAcurex Biosciences Awarded ASAP Grant to Advance Breakthrough Approach to Parkinson’s DiseaseAcurex Biosciences announced it has been awarded a multi-year grant from Aligning Science Across Parkinson’s (ASAP) in partnership with The Michael J. Fox Foundation to fund a collaboration led by Dr. Tim Greenamyre of the University of Pittsburgh, along with researchers from King’s College London. The funding will support research targeting the 15-lipoxygenase (15-LO) enzyme as a potential approach to protect dopamine-producing brain cells and slow or halt Parkinson’s disease progression rather than merely managing symptoms. The company, which is preparing to raise Series A funding, joins ASAP’s Collaborative Research Network to advance its lead drug candidates toward human clinical trials.NewswiseUCLA to Lead $9M Study on Pesticides’, Air Pollutants’ Link to Parkinson’s Disease RiskUCLA Health will lead a $9 million, three-year research project funded by Aligning Science Across Parkinson's and The Michael J. Fox Foundation for Parkinson's Research to study the link between exposure to pesticides, air pollution, and increased Parkinson's disease risk. The multi-institution study involves researchers from UCLA, Cedars-Sinai, University of Münster in Germany, and University of Dundee, who will analyze populations exposed to toxicants, stem cells, and animal models to identify molecular pathways driving neurodegeneration. Previous UCLA research in the Central Valley found higher Parkinson's risk associated with exposure to pesticides such as chlorpyrifos and paraquat, and air pollutants like small particulate matter.PR NewswireAligning Science Across Parkinson's and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized TreatmentsAligning Science Across Parkinson's (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson's Research, announced $261 million in new grant funding for the Collaborative Research Network (CRN) to support 32 international research teams studying the heterogeneity of Parkinson's disease and advancing precision medicine. With this round, ASAP's total CRN investment exceeds $550 million, funding 67 teams of nearly 400 investigators across 187 institutions in 24 countries. The funding will support research into environmental and genetic risk factors, co-pathologies, aging-related immune changes, and brain circuit disruption, while also generating standardized research tools including CRISPR cell lines and viral vectors for the global scientific community.BioSpaceAligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized TreatmentsAligning Science Across Parkinson's and The Michael J. Fox Foundation announced $261 million in new grant funding for 32 international teams to study Parkinson's disease heterogeneity. The funding brings ASAP's total CRN investment to over $550 million, supporting research into disease variation and personalized treatments.InsideprecisionmedicineNeeded ASAP: The Partnership Rewiring Neurodegeneration ResearchThe Coalition for Aligning Science (CAS) launched the Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, a global initiative funded by the Michael J. Fox Foundation and Sergey Brin to harmonize biomedical data across 35 multidisciplinary teams. ASAP has partnered with the Allen Institute to integrate its CRN Cloud data into broader neurodegenerative disease research, significantly expanding existing datasets on cell types and pathologies like Alzheimer's.GlobeNewswireAligning Science Across Parkinson’s (ASAP) launches a second funding opportunity to accelerate novel tool development to advance Parkinson's disease researchASAP opened applications for a second funding opportunity to accelerate novel tool development for Parkinson's disease research. Grants offer up to $2M per year over three years, totaling $6M, with Letter of Intent submissions due May 5, 2025. Funding decisions are expected in February 2026.GlobeNewswireAligning Science Across Parkinson’s (ASAP) Launches a New Funding Opportunity to Join the Collaborative Research NetworkASAP opened applications for the Collaborative Research Network 2025 Scientific Track, offering up to $3 million per year over three years for teams studying Parkinson's disease heterogeneity. Teams must adhere to ASAP guidelines and open science policy, with letter-of-intent submissions due March 20, 2025 and funding decisions in January 2026.